LD-2 disclosure · 2nd Quarter - Report
APOTEX CORP.
via APOTEX CORP.
Client
- Name
- APOTEX CORP.
- Location
- Florida · United States of America
Registrant
- Firm
- APOTEX CORP.
- Description
- Generic pharmaceutical manufacturer
- Location
- WESTON, Florida, United States of America
Lobbying activities
3 issuesManufacturing
Federal policy relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs.
LobbyistsSTEVEN GIULI
TargetedSENATE · HOUSE OF REPRESENTATIVES · Office of Management & Budget (OMB) · Bureau of Industry and Security (BIS) · Natl Economic Council (NEC)
Health Issues
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; and Federal policy relating to the structure of the Department of Health and Human Services.
LobbyistsSTEVEN GIULI
TargetedSENATE · HOUSE OF REPRESENTATIVES · Natl Security Council (NSC) · Office of Management & Budget (OMB) · U.S. Trade Representative (USTR) · Natl Economic Council (NEC)
Tariff (miscellaneous tariff bills)
Executive Order 14231, Amendment to Duties To Address the Flow of Illicit Drugs Across our Northern Border, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals from such tariffs; Executive Order 14257, Regulating Imports With A Reciprocal Tariff To Rectify Practices That Contribute To Large And Persistent Annual United States Goods Trade Deficits, provisions relating to the exemption of pharmaceuticals from reciprocal tariffs; Federal policy relating to the Department of Commerce's Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [Docket No. 250414-006] and the exemption of pharmaceuticals compliant with the United States-Mexico-Canada trade agreement from any tariffs implemented following the completion of the Section 232 investigation;